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Abstract
The glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase widely expressed in mammalian tissues. Ini-
tially identified by its ability to modulate glycogen synthesis, GSK-3 turned out to be a multifunctional enzyme, able
to phosphorylate many proteins, including members of the steroid receptor superfamily. Although GSK-3 was
shown to phosphorylate the androgen receptor (AR), its effects on AR transcriptional activity remain controversial.
Analysis of short hairpin RNA (shRNA)–mediated downmodulation of GSK-3 proteins in prostate cancer cells
showed a reduction in AR transcriptional activity and AR protein levels. Pharmacological GSK-3 inhibitors such
as the maleimide SB216763 or the aminopyrazole GSK inhibitor XIII inhibited AR-dependent reporter gene activity
and AR expression in vitro. Analysis of androgen-induced nuclear translocation of the AR was performed in PC3
cells transfected with pAR-t1EosFP coding for EosAR, a green fluorescent AR fusion protein. When grown in pres-
ence of androgens, EosAR was predominantly nuclear. Incubation with SB216763 before and after androgen treat-
ment almost completely reduced nuclear EosAR. In contrast, the thiazole-containing urea compound AR-A014418
increased rather than decreased AR–expression/function. Although not all GSK inhibitors affected AR–stability/
function, our observations suggest a potential new therapeutic application for some of these compounds in pros-
tate cancer.
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Introduction
Prostate cancer (PCa) is very heterogeneous in its etiology and progres-
sion, but androgen signaling seems to be a key element in its develop-
ment and progression. Two important androgens, testosterone and its
metabolite dihydrotestosterone, mediate their effects through the an-
drogen receptor (AR), a member of the steroid receptor superfamily.
In the early stage of the disease, most patients respond favorably to
androgen ablation therapy. However, a major problem of these treat-
ments is the progression of androgen-dependent tumors to a hormone
refractory state. Although the molecular basis for this phenomenon is
largely unknown, studies of tumor specimens indicate that the AR sig-
naling pathway is still functional in hormone refractory PCa [1]. Tran-
scriptional activity of AR correlated with its phosphorylation status.
Alteration of AR phosphorylation by protein kinases in PCa cells
may provide a mechanism to circumvent the growth-inhibitory effects
caused by androgen ablation.
The glycogen synthase kinase 3 (GSK-3) is a serine/threonine ki-
nase widely expressed in mammalian tissues. In humans, two highly
conserved isoforms, GSK-3α and GSK-3β, that share a 97% se-
quence homology within their kinase domains have been cloned
[2]. Initially identified by the ability to modulate glycogen synthesis,
GSK-3 turned out to be a multifunctional enzyme, able to phosphor-
ylate many proteins, including members of the steroid receptor su-
perfamily [3–5]. Although GSK-3 has been recently shown to
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phosphorylate AR, its effects on AR-mediated transcriptional activity
are discussed controversially [3,6–8].
In this report, we screened different novel pharmacological GSK-3
inhibitors for their effect on androgen action in human AR-positive
PCa cells. To elucidate the functional relationship of GSK-3 and AR
and to specify the specific role of GSK-3 in the signaling processes
related to androgen-dependent AR activation, we used different meth-
odological approaches including RNA interference targeting GSK-3
and various specific chemical inhibitors of GSK-3 function. Here,
we show that short hairpin RNA (shRNA)–mediated downmodula-
tion of GSK-3β-protein in 22Rv1 PCa cells exhibit a reduction in
AR transcriptional activity and in AR protein levels. Inhibition of
GSK activity by chemical inhibitors like the maleimide, SB216763
or the aminopyrazole, GSK inhibitor XIII diminished AR-dependent
reporter gene activity and AR expression in 22Rv1 and LNCaP cells.
Analysis of androgen induced nuclear translocation of the AR was per-
formed in PC3 cells transfected with an expression plasmid coding for
a green fluorescent EosAR fusion protein. Interestingly, treatment of
PC3 cells with SB216763 or GSK inhibitor XIII almost completely
inhibited androgen-induced nuclear import of the EosAR. When cells
were preincubated with synthetic androgen R1881, treatment with
SB216763 and GSK inhibitor XIII decreased nuclear localization of
EosAR dramatically within 30 minutes after GSK inhibition. To our
knowledge, this is the first report to link the nuclear export of the AR
to GSK-3 activity. In contrast to SB216763 and GSK inhibitor XIII,
the thiazole-containing urea compound AR-A014418, another highly
potent GSK-3 inhibitor, increased rather than decreased AR activity
and AR expression.
The present results suggest that GSK-3 modulates AR-stability
and different AR-functions. Although not all GSK inhibitors affected
AR–stability/function, some of these compounds could play a role in
new therapeutic approaches for the treatment of PCa.
Materials and Methods
Plasmids
T-cell factor (TCF) reporter plasmids pTopFlash (TOP) and pFop-
Flash (FOP), containing three copies of wild type or mutant TCF-
binding sites upstream of a thymidine kinase minimal promoter driving
a luciferase gene and the mammalian GSK-3 siRNA expression plasmid
pKD-GSK-3β-v1 and its control plasmid pKD-NegCon-v1 were prod-
ucts of Upstate Biotechnology, Lake Placid, NY. The probasin pro-
moter luciferase reporter plasmid (pGL3Eprob) containing a 267-bp
fragment of the rat probasin gene promoter (base positions −256 to
+ 11) was a gift from Dr. Z. Culig, Innsbruck, Austria. pAR-t1EosFP,
an expression vector coding for EosAR, a green fluorescent AR fusion
protein, was a generous gift from Dr. J Wiedenmann, Ulm, Germany.
pRL-tk-LUC Renilla reniformis luciferase reporter plasmid, used as an
internal control for transfection efficiencies, was a product of Promega,
Mannheim, Germany.
Figure 1. Silencing of GSK-3 in 22Rv1 cells. (A) GSK-3–directed
shRNA diminishes GSK-3 protein expression: 22Rv1 cells were
transfected with shRNA directed either against GSK-3 (pKD-GSK-
3β-v1) or control shRNA (pKD-NegCon-v1). A total of 30 μg of pro-
tein extracts from the transfected cells was isolated after 48 and
96 hours and subsequently analyzed by Western blot. (B) Densito-
metric analysis of GSK-3 and AR-expression after GSK-3 silencing:
22Rv1 cells were transfected with shRNA directed against GSK-3 as
described in the Materials and Methods section. Cell extracts were
isolated after 48 and 96 hours, respectively. Expression of GSK-3
and AR-protein after GSK-3 silencing was quantified by densi-
tometry using ChemiCapt/Bio1D software from Vilber Lormat. GSK
and AR-protein expression were normalized to actin. Results rep-
resent the mean of three independently analyzed Western blots
and are expressed in % of untreated controls which were set
at 100% (% AR/Actin and % GSK/Actin). (C) Silencing of GSK-3
by shRNA diminishes AR-signaling: 22Rv1 were cotransfected with
pKD-GSK-3-v1 or pKD-NegCon-v1 and with pGL3Eprob and pRL-
tk-LUC. After transfection, cells were grown for 48 hours. Subse-
quently, cells were incubated with/without 5-nM R1881 for another
24 hours. After androgen treatment, AR-reporter gene activity was
determined as described in the Materials and Methods section. Re-
sults are expressed as in % of untreated controls (which were set at
100%) ± SD.
Table 1. GSK-3 In Vitro Kinase Assay.
GSK-3 Inhibitor Concentration (μM) % Inhibition
SB216763 2.5 33 ± 8
AR-A014418 2.5 95 ± 3
GSK inhibitor XIII 2.5 34 ± 14
Pharmacological GSK-3 inhibitors were mixed with GSK-3 kinase, GSK-3 substrate and ATP-
solution as described in the Materials and Methods section. The mixture was subsequently incu-
bated for 30 minutes at 30°C. Kinase reaction was stopped by an equal volume of Kinase-Glo
reagent and luminescence was measured after 10 minutes.
% Inhibition was determined as: 100 × (luminescence of GSK-3 inhibitor − positive control)/
(negative control − positive control).
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GSK-3β Inhibitors
GSK-3β inhibitor AR-A014418 (N-4-methoxybenzyl-N-5-nitro-1,3-
thiazol-2-yl) and GSK-3β inhibitor XIII (5-methyl-1H-pyrazol-3-yl-2-
phenylquinazolin-4-yl amine) were purchased from Calbiochem,Merck
Biosciences, Darmstadt, Germany. SB216763 (3-(2,4-dichlorophenyl)-
4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione) was provided by
Biomol GmbH, Hamburg, Germany.
Tissue Culture Materials
Androgen receptor–negative PCa cell lines PC3 and the AR receptor-
positive LNCaP and 22Rv1 cell lines were purchased from the
American Type Culture Collection, Manassas, VA. The AR-positive,
hormone refractory PCa cell line LNCaP-SSR [9] was a gift from
Dr. M. Burchardt, Hannover, Germany. RPMI 1640 was purchased
from Gibco Invitrogen GmbH, Karlsruhe, Germany. Fetal bovine se-
rum (FBS) was a product of Sigma, Taufkirchen, Germany. Steroid-free
dextran-charcoal–treated FBS (FBSdcc) was from Biochrom AG, Berlin,
Germany, and BioWest, Nuaille, France. Penicillin/streptomycin solu-
tion was a product of PAA Laboratories, Linz, Austria. The synthetic
androgen methyltrienolone R1881 was provided by New England
Nuclear, Dreieichenhain, Germany. All other chemicals were products
of Sigma (Taufkirchen, Germany).
Tissue Culture
Cells were routinely maintained in RPMI 1640, supplemented with
penicillin/streptomycin and 10% FBS (PC3, LNCaP, and 22Rv1) or
10% FBSdcc (LNCaP-SSR). During experiments, cells were cultured
in RPMI 1640 with 2.5% FBSdcc and antibiotics in the presence/
absence of the synthetic androgen methyltrienolone R1881.
Table 2. Effects of GSK-3 Inhibitors on AR and TCF/LEF Signaling and GSK-3 Activity In Vitro.
GSK-3β Inhibitor Class AR Signaling TCF-4/LEF Signaling Kinase Assay
22Rv1 LNCaP LNCaP-SSR 22Rv1 (AR+) PC3 (AR−)
AR-A014418 Thiazole urea ↑↑ ↑↑ ↑↑ ↑ ↑ ↓↓
SB216763 Maleimide ↓↓ ↓↓ ↓ ↑↑ ↑ ↓
GSK inhibitor XIII Aminopyrazole ↓ ↓ ↓ ↑ ND ↓
pKD-GSK-3β-v1 shRNA ↓ ND ND ↑↑ ND —
ND indicates not determined.
Figure 2. Modulation of AR transactivation by pharmacological GSK-3 inhibitors. AR-receptor–positive cell lines 22Rv1, LNCaP, and
LNCaP-SSR were incubated with different pharmacological GSK-3 inhibitors in the presence/absence of 5-nM R1881 for 96 hours.
AR transcriptional activity was measured using an AR-reporter gene assay. Results are expressed in % of untreated controls (without
R1881, without inhibitors).
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Reporter Gene Assays
Androgen receptor signaling and WNT/β-catenin signaling were
analyzed by reporter gene assays as recently described [10]. In brief,
cells were seeded in 24-well plates and allowed to grow overnight. Sub-
sequently, cells were transiently cotransfected with pGL3Eprob and
pRL-tk-LUC (AR signaling) or pTOPFlash/pFOPFlash and pRL-tk-
LUC (WNT/β-catenin signaling) using FuGene6 (Roche Diagnostics
Corporation, Basel, Switzerland). At 24 hours after transfection, cells
were treated with different GSK-3β inhibitors in the presence/absence
of the synthetic androgen R1881. Reporter activity was assessed after a
48-hour incubation period using the Dual-Luciferase Reporter Assay
System (Promega). Luminescence was measured using Lumat LB
9507, Berthold Technologies, Bad Wildbad, Germany. Firefly lucifer-
ase activities of the reporter constructs were normalized by Renilla lu-
ciferase activities. All experiments were performed at least in triplicates.
GSK-3 In Vitro Kinase Assay
GSK-3 activity was determined using the Kinase-Glo Luminescent
Kinase Assay Platform from Promega. Human recombinant GSK-
3β-kinase was provided by Cell Signaling Technology (New England
Biolabs GmbH, Frankfurt am Main, Germany), the GSK-3 substrate
representing a part of the hydrophilic loop domain of presenilin 1 was
a product of Calbiochem (Merck Biosciences). The Kinase-Glo
Luminescent Kinase Assay was performed according to the manufac-
turer’s instructions. In short, 10 μl of GSK-3β inhibitor (concentra-
tion, 10 μM) was mixed with 10 μl of GSK-3 kinase (20 ng), 10 μl
of a 25-μM GSK-3β substrate solution, and 10 μl of a 1-μM ATP
solution. This mixture was subsequently incubated for 30 minutes at
30°C. The kinase reaction was stopped by adding 40 μl of Kinase-
Glo reagent. Luminescence was measured after 10 minutes using
Lumat LB 9507 (Berthold Technologies).
Nuclear Translocation Assays
Nuclear translocation of AR was analyzed in PCa cells transfected
with a green f luorescent AR fusion protein [11]. Therefore, PC3
prostate cancer cells were seeded into 24-well tissue culture plates
and allowed to adhere overnight. Subsequently, cells were transfected
with the green f luorescent reporter construct pAR-t1EosFP (0.25 μg/
well) for 4 hours in RPMI and allowed to grow for another 24 hours
in RPMI 1640 supplemented with 5% FBSdcc and antibiotics. There-
after, cells were grown in RPMI supplemented with 2.5% FBSdcc in
the presence/absence of 5-nM R1881 for 6 hours. For each well, 30
fluorescent cells were counted, and AR distribution was categorized as
nuclear staining (ncl), cytoplasmatic staining (cyto), or nuclear and cy-
toplasmatic staining (ncl + cyto). Experiments were done in triplicates.
Results are expressed in % ± SD.
Western Blot Analysis
Whole-cell extracts from transfection assays were used for Western
blot analysis of the AR protein and GSK-3β protein. Protein concen-
tration of the cell extracts was determined using the BCA–Protein
Assay (Pierce, Rockford, IL). Protein extracts (20–30 μg) were elec-
trophoresed in a 10% SDS-PAGE and electroblotted onto nitrocel-
lulose membranes. Nonspecific binding was blocked by incubation
with 5% nonfat dry milk in phosphate-buffered saline. Subsequently,
membranes were incubated with a rabbit polyclonal AR antibody
(1:800; Cell Signaling Technology) or with a mouse monoclonal
GSK-3β antibody (1:5000; BD Biosciences Pharmigen, Becton
Dickinson GmbH, Heidelberg, Germany). Incubation with mouse
monoclonal antibody AC-15 to β-actin (1:9000; Biozol Diagnostica,
Eching, Germany) served as a loading control. Immunoreactive
bands were detected using peroxidase-labeled antirabbit or antimouse
antibodies [1:1500, Goat Anti–Rabbit IgG peroxidase conjugate
(Pierce) and 1:5000, Goat Anti–Mouse IgG peroxidase conjugate
(Sigma)]. Androgen receptor bands were visualized either by en-
hanced chemiluminescence (ECL; Amersham Pharmacia Biotech,
Buckinghamshire, UK) with a subsequent exposure to an ECL film
or by direct detection using a ChemiSmart 500, Vilber Lormat,
Marne-la-Vallee, France. Immunoreactive bands were quantified by
desitometry using ChemiCapt/Bio1D software from Vilber Lormat.
Cell Proliferation Assay
Cellular proliferation was assessed by means of a colorimetric
MTT assay measuring the reduction of tetrazolium salts to formazan
Figure 3. Androgenic properties of the GSK-3 inhibitor AR-A014418.
(A) AR-A014418 activates the AR in absence of androgens: 22Rv1
cells were treated for 30 hours with AR-A014418 in the absence of
androgens. AR-activity was determined using an AR-reporter gene
assay as described in the Materials and Methods section. Results
are expressed in % of untreated controls ± SD. (B) AR-A014418
stimulates nuclear translocation of the AR in the absence of andro-
gens: PC3 cells grown in a 24-well plate, were transfected with
pAR-t1EosFP, a plasmid coding for a green fluorescent AR-fusion
protein. Subsequently, cells were treated with different amounts
of AR-A014418 and incubated for 4 hours. After this, green fluores-
cent cells were counted using a fluorescence microscopy (30 cells/
well). Results are expressed in % of green fluorescent nuclei ± SD.
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derivatives by functional mitochondria. The assay was performed as
recently described [11].
Statistical Analysis
Data are reported as mean ± SD. Analysis was performed with Stu-
dent’s t test with P < .05 considered as significant.
Results
GSK-3 Silencing Decreases AR Transcriptional Activity
Previous studies analyzing the effects of GSK-3 on AR signaling
using lithium chloride yielded controversial results [6–8]. To determine
whether AR transcriptional activity is dependent on GSK-3, we re-
duced cellular GSK-3 protein levels using a commercial shRNA di-
rected against GSK-3 (pKD-GSK-3β-v1; Upstate). The efficiency to
down-regulate GSK-3 was monitored by Western blot analysis (Fig-
ure 1, A and B). Treatment of 22Rv1 cells with GSK-3β–shRNA in
the presence of R1881 (5 nM) significantly reduced transcriptional ac-
tivity of the AR by 50% (P < .0001; Figure 1C ). Inhibition of tran-
scriptional activity was paralleled by a decrease in AR protein as shown
by densitometry of three independent Western blots (Figure 1B).
Inhibition of GSK-3β Activity Modulates AR
Transcriptional Activity
To determine the effects of a functional inhibition of GSK-3 on
AR signaling, the AR-positive cells 22Rv1, LNCaP, and the hormone
refractory LNCaP subline LNCaP-SSR were treated with different
novel pharmacological inhibitors of GSK-3. The capability of the
compounds to reduce the enzymatic activity of recombinant human
GSK-3β in vitro was determined using a commercial luminescent ki-
nase assay (Table 1). The efficiency of the inhibitors to down-regulate
GSK-3 activity in vivo was determined indirectly using a β-catenin–
inducible reporter gene assay. This approach is based on the principle
that under normal conditions GSK-3 is a part of a multiprotein com-
plex that targets free intracellular β-catenin for degradation. Inactiva-
tion of the enzyme leads to an increase in intracellular β-catenin that
acts as a cofactor for the activation of TCF transcription factors. The
increase of intracellular β-catenin was measured by a TCF-specific
Figure 4. Effects of GSK-3 inhibitors on AR-protein expression. Cell extracts isolated from AR-reporter gene assays were analyzed by
Western blot analysis as described in the Materials and Methods section. Inhibition of AR-transactivation by pharmacological inhibitors
of GSK-3 was paralleled by a decrease in AR-protein expression.
Figure 5. Downmodulation of AR by GSK-3 is due to proteasomal
degradation. LNCaP cells were incubated with/without 5 μM of
the proteasome inhibitor MG132 for 60 minutes, followed by a
SB216763 treatment (final concentration, 1 μM) for another 60 min-
utes. Subsequently, R1881 (5 nM) was added to the medium, and
the cells were grown for another 6 hours. Subsequently, cell ex-
tracts were analyzed by Western blot analysis.
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reporter gene assay (pTOPFlash, pFOPFlash). All GSK-3 inhibitors
SB216763, AR-A014418, GSK inhibitor XIII, and shGSK-3β were
able to increase intracellular β-catenin, suggesting that they are active
in vivo (Table 2).
Effects of the inhibitors on AR signaling were monitored by the
probasin reporter gene assay (Figure 2). In the presence of the male-
imide SB216763, AR signaling was dose-dependently inhibited in all
three cell lines. The inhibitory effects were already measurable
at a concentration of 1-μM SB216763 ranging from 21% in LNCaP
to 38% in 22Rv1 and 46% in LNCaP-SSR (Figure 2). At a concen-
tration of 10-μM SB216763, the transcriptional activity of AR was
diminished in LNCaP and 22Rv1 by 40% and more than 60%, re-
spectively (Figure 2). Similar results could be achieved in all three cell
lines with the aminopyrazole GSK-3 inhibitor XIII (Figure 2).
Although the GSK-3 inhibitor, AR-A014418, a thiazole-containing
urea compound, inhibited GSK-3 activity as did SB216763 or GSK
inhibitor XIII (Tables 1 and 2), to our surprise, this inhibitor increased
rather than decreased AR signaling in 22Rv1, LNCaP, and LNCaP-
SSR in a dose-dependent manner. The most significant increase in
AR signaling (>70% in 22Rv1 and LNCaP cells) was already measur-
able at a concentration of 0.25-μM AR-A014418.
Enhancement of AR Signaling By AR-A014418 Is Due to
Androgenic Properties of the Compound
SB216763, GSK inhibitor XIII, and AR-A014418 inhibit GSK-3
function in an ATP-competitive manner (Tables 1 and 2). To explain
the increase in AR signaling after AR-A014418 treatment, we tested
Figure 6. Effects of GSK-3 inhibitors on nuclear translocation of the EosAR. (A) Fluorescence microscopy of pAR-t1EosFP–transfected
PC3 cells: (a) absence of androgens, (b) presence of androgens, (c) preincubation with SB216763 before androgen treatment, and (d)
pretreatment with AR-A014418 before androgen treatment. (B) Percentage of cells exhibiting predominantly nuclear (black bars) or cy-
toplasmatic fluorescence (white bars) and even cytoplasmatic and nuclear fluorescence (gray bars).
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whether the compound itself exhibits androgenic properties. There-
fore, 22Rv1 cells were treated with increasing concentrations of
AR-A014418 in the absence of androgens. Indeed, AR-A014418 in-
creased probasin reporter gene activity in a dose-dependent manner
(Figure 3A). At an AR-A014418 concentration of 3 μM, androgen-
dependent reporter gene activity was increased by >360% compared
with the untreated controls (Figure 3A). Moreover, AR-A014418 was
able to induce nuclear translocation of the green f luorescent fusion
protein EosAR in PC3 (Figure 3B). In the absence of androgens, ap-
proximately 5% of the EosAR was nuclear, increasing to >20% in the
presence of 0.5-μM AR-A014418 to more than 40% in presence of
2 μM of the compound. In contrast, the GSK-3 inhibitor SB216763
was unable to induce probasin reporter gene activity and nuclear im-
port of the AR. We conclude that the positive effects of the thiazole-
containing urea compound AR-A014418 on AR signaling is due, at
least in part, to the androgenic properties of the compound.
Downmodulation of AR Signaling By GSK-3 Inhibitors Is
Paralleled By a Degradation of AR protein
Inhibition of GSK-3 has recently been shown to influence estrogen
receptor (ER) stability in MCF-7 cells [12]. Similar to the experiments
with GSK-3–shRNA, all functional GSK-3 inhibitors, able to inhibit
AR signaling, decreased AR proteins in 22Rv1, LNCaP, and LNCaP-
SSR PCa cells (Figures 1 and 4). In contrast to SB216763 and GSK
inhibitor XIII, AR-A014418 was unable to decrease but increased
intracellular AR protein levels in all three cell lines (Table W1). Fur-
thermore, this observation supports the assumption that AR-A014418
acts like an androgen, stabilizing the AR on binding. The down-
regulation of AR protein by SB216763 could be rescued by MG-132,
an inhibitor of proteasomal degradation, suggesting an important
role of GSK-3 in the stabilization of the AR molecule (Figure 5;
Table W2).
Inhibition of GSK-3 Activity By SB216763 and GSK
inhibitor XIII Modulates Nuclear Translocation of the AR
GSK-3 has been shown to modulate nuclear translocation of var-
ious proteins and transcription factors; however, its effect has not
been shown in members of the steroid receptor superfamily. In con-
sequence, we tested the effects of a GSK-3 inhibition on the ability of
the AR to translocate in the nucleus on androgenic stimulation. There-
fore, we transfected the AR-negative PC3 cells with pAR-t1EosFP, a
plasmid coding for an AR protein fused to the GFP-like Eos protein
[11]. In the absence of androgens, the fusion protein EosAR was pre-
dominantly present in the cytoplasm (>90%; Figure 6). On andro-
genic stimulation, more than 90% of EosAR translocated into the
nucleus within 30 minutes (Figure 6B). When PC3 cells were incu-
bated with SB216763 before androgen treatment, nuclear import of
EosAR was completely inhibited as can be seen by the >90% cytoplas-
matic staining of EosAR (Figure 6B). Similar results could be obtained
with GSK inhibitor XIII and GSK-3–shRNA, although the effects on
nuclear translocation were less pronounced (data not shown). Most
interestingly, SB216763 was able to induce a nuclear export of EosAR
in PC3 cells pretreated with 5-nM R1881. The compound was able to
reduce the predominant nuclear localization of EosAR from more than
90% in the presence of R1881 to basal levels (Figure 7). Export of the
AR was already measurable after 30 minutes, suggesting an active
transport of EosAR from the nucleus to the cytoplasm. In addition,
similar experiments in 22Rv1 cells and replacement of pAR-t1EosFP
by a GFP-tagged AR construct yielded identical results (data not
shown). In contrast, AR-A014418 had no effect on the nuclear export
of EosAR (Figure 7).
Effects of SB216763 and AR-A014418 on PCa Cell Growth
On the basis of the previous results, we examined the effects of the
GSK-3 inhibitors SB216763 and AR-A014418 on PCa cell growth.
When grown in RPMI 1640 supplemented with 2.5% FBS in the pres-
ence of SB216763 (10 μM), the proliferation of the AR-positive cell
lines 22Rv1 and LNCaP was inhibited by 32% and 29%, respectively
(Figure 8A). In contrast, the proliferation rate of the AR-negative PC3
cells remained almost unaffected under these conditions. These findings
are in perfect agreement with a previous study of Mazor et al. [6], an-
alyzing the effects of SB216763 on the proliferation of PCa cells. Most
interestingly, the GSK-3 inhibitor AR-A014418 slightly enhanced the
proliferation of the androgen-sensitive LNCaP cells (Figure 8A).
In the absence of androgens (2.5% FBSdcc), AR-A014418 stim-
ulated the growth of androgen-responsive LNCaP cells in a dose-
dependent manner, reaching its maximum at 1.5 μM of AR-A014418
(126 ± 8% compared with untreated controls which were set at
100%), whereas proliferation of the AR-negative PC3 cells remained
unaffected under the same conditions (Figure 8B). We conclude that
the positive effects of the thiazole-containing urea compound AR-
A014418 on the proliferation of LNCaP are due to the androgenic
properties of the compound.
Discussion
Prostate cancer is the most commonly diagnosed cancer and the
second leading cause of male cancer deaths in the western world.
Although PCa is very heterogeneous in its etiology, AR signaling
seems to be a key element in its development and progression. As
PCa cells depend on androgens for growth and survival antiandrogen
therapy involving androgen depletion by orchiectomy, treatment with
LHRH-analogues and blockade of AR with antiandrogens are standard
treatments for patients experiencing advanced PCa. However, a major
clinical problem of these treatments is the progression of androgen-
dependent tumors to a hormone refractory state. Although the molecular
Figure 7. Inhibition of GSK-3 by SB216763 induces a rapid export of
EosAR from the nucleus. PC3 cells grown in a 24-well plate were
transfected with pAR-t1EosFP. Subsequently, cells were treated
with 5-nM R1881 for 30 minutes resulting in a >90% of nuclear
EosAR. Subsequently, cells were treated with/without 1-μM
SB216763 or 1.5-μM AR-A014418 for 30 and 240 minutes. Fluores-
cent cells were counted using fluorescence microscopy (30 cells/
well). Results are expressed in % of green fluorescent nuclei ± SD.
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basis for this phenomenon is largely unknown, studies of tumor speci-
mens indicate that the AR signaling pathway is still functional in hor-
mone refractory PCa.
The AR is a ligand-dependent transcription factor of the steroid re-
ceptor superfamily. Like all steroid receptors, the AR is structurally or-
ganized in three different domains: an amino-terminal transactivation
domain, a well-conserved central DNA-binding domain with two zinc
finger motifs required for DNA binding and a ligand-binding domain
at the carboxy-terminal region of the protein. The DNA-binding do-
main and the ligand-binding domain are linked by the hinge region
containing a nuclear export signal [13]. On androgen binding, the
AR dimerizes and the AR–ligand complex translocates to the nucleus
where it binds the DNA at specific androgen response elements to in-
duce the transcription of androgen-dependent genes. Transcriptional
activity of the AR is correlated with its phosphorylation status. Alter-
ation of AR phosphorylation by protein kinases in PCa cells are
thought to provide a mechanism enabling the cells to circumvent
the growth-inhibitory effects caused by androgen ablation.
The GSK-3 is a serine/threonine kinase widely expressed in mam-
malian tissues. In humans, two highly homologous forms of GSK-3,
GSK-3α and GSK-3β, that share a 97% sequence homology within
their kinase domains have been cloned [2]. Initially identified by the
ability to modulate glycogen synthesis, GSK-3 turned out to be a
multifunctional enzyme, able to phosphorylate many proteins, in-
cluding members of the steroid receptor superfamily [3–5]. Although
GSK-3 has been recently shown to phosphorylate the AR, its effects
on AR-mediated transcriptional activity are still discussed controver-
sially. In 2004, four groups independently reported that transcriptional
Figure 8. Effects of GSK-3 inhibitors on prostate cancer cell growth. (A) Modulation of cell growth by AR-A014418 and SB216763 in the
AR-positive cell lines 22Rv1 and LNCaP: 22Rv1, LNCaP, and PC3 prostate cancer cells were seeded in 96-well plates and allowed to
adhere overnight. Subsequently, medium was changed, and cells were grown for 72 hours in RPMI 1640, supplemented with 2.5% FBS
and antibiotics in the presence/absence of 10-μM SB216763 or 1-μM AR-A014418. Proliferation was measured by means of a colori-
metric MTT assay. Results are expressed in % of untreated controls, which were set at 100%. (B) AR-A014418 stimulates androgen-
sensitive LNCaP cells in the absence of androgens: LNCaP (AR+) and PC3 (AR−) prostate cancer cells were seeded in 96-well plates
and allowed to adhere overnight. Subsequently, medium was changed, and cells were grown for 96 hours in an androgen-free medium
(RPMI 1640, supplemented with 2.5% FBSdcc and antibiotics) in the presence of increasing concentrations of AR-A014418. Prolifera-
tion of the cells was measured by means of a colorimetric MTT assay. Results are expressed in % of untreated controls.
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activity of the AR is regulated by GSK-3. Whereas Salas et al. [3] and
Wang et al. [7] reported that GSK inhibits AR transactivation, Mazor
et al. [6] and Liao et al. [8] found that GSK-3 activity is required for
androgen-stimulated gene expression and, in consequence, that inhibi-
tion of GSK-3 represses AR activity in PCa cells.
To elucidate the specific role of GSK-3 in the signaling processes
related to androgen dependent AR activation we used RNA inter-
ference targeting GSK-3 and three specific chemical inhibitors of
GSK-3 function. Depletion of GSK-3–protein by shRNA signifi-
cantly down-regulated AR transcriptional activity in 22Rv1 cells
grown in the presence of R1881 (Figure 1C ). Moreover, depletion
of GSK-3 by shRNA led to a downmodulation of AR protein (Fig-
ure 1B). Inhibition of GSK activity by chemical inhibitors such as
the maleimide SB216763 or the aminopyrazole GSK inhibitor XIII
diminished AR-dependent reporter gene activity in 22Rv1, LNCaP,
and LNCaP-SSR cells (Figure 2). The reduction of AR transcrip-
tional activity was paralleled by a proteasomal degradation of AR pro-
tein as shown for the cell lines 22Rv1 and LNCaP (Figures 4 and 5).
These observations are in agreement with a previous study, reporting
a downmodulation of AR protein using SB216763 [6]. Furthermore,
the results are supported by previous studies on the ER showing that
GSK-3 inhibition destabilizes ER protein expression, thereby modu-
lating full transcriptional activity of the receptor [4,12].
Androgen receptor protein expression and function are critical de-
terminants for the survival and proliferation of PCa cells. Indeed,
PCa cells tolerate only a narrow range of AR expression and activity
[14]. The AR expression is delicately regulated to provide an optimal
balance between AR and its cofactors or repressors as has been shown
for AR and p53 [15]. Besides its ability to function as an inducible
transcription factor, there is experimental evidence from PCa cells
that the AR is a licensing factor for DNA replication that must be
degraded through a proteasome-dependent pathway during each
cell cycle to allow reinitiation of DNA replication in the next cell
cycle [16]. Modulation of intracellular AR protein/activity through
GSK-3 makes the enzyme an interesting target for therapeutical ap-
plications. At present, there are numerous pharmacological GSK-3
inhibitors on the market but not all are able to inhibit AR signaling.
As shown in our study, the GSK inhibitor SB216763 decreased AR-
functions and AR expression. Downmodulation of AR-function was
paralleled by an inhibition of PCa cell growth in the AR-positive cell
lines 22Rv1 and LNCaP. In contrast, the highly specific GSK-3 in-
hibitor AR-A014418 increased rather than decreased AR activity and
AR expression in PCa cells. Moreover, AR-A014418 was able to
stimulate the proliferation of the AR-responsive LNCaP cells in
the absence of androgens (Figure 8B). We presume that these effects
are due to the androgenic properties of AR-A014418, showing that
not all potent GSK-3 inhibitors are suitable per se to downmodulate
AR activity.
Most interestingly, inhibition of GSK function by SB216763 and
GSK-3 inhibitor XIII had a dramatic effect on the nuclear transloca-
tion of EosAR, a green fluorescent AR fusion protein (Figures 6 and 7)
[11,17]. When PCa cells were treated with SB216763 or GSK inhib-
itor XIII 2 hours before an androgenic stimulus, the nuclear import
of EosAR was almost completely inhibited (Figure 6). PCa cells co-
transfected with GSK-3–shRNA and pAR-t1EosFP showed similar
results although not that pronounced (data not shown). When
PCa cells were preincubated with synthetic androgen R1881, treat-
ment with SB216763 and GSK inhibitor XIII decreased nuclear lo-
calization of EosAR from 93% to 32% within 30 minutes after GSK
inhibition. To our knowledge, this is the first report to link the nu-
clear export of the AR to GSK-3 activity.
The abundance of the AR inside the nucleus is tightly regulated by
numerous factors that control nuclear import, binding to androgen
response element, export and degradation of the AR import, export
[11,18]. The fact how GSK-3 modulates nuclear translocation of the
AR remains unknown. On the basis of in silico data Ser424, Ser514,
and Ser650 have been identified as putative AR phosphorylation sites
that could be phosphorylated by GSK-3 [19]. Among these, the po-
sition Ser650, located proximal to the DNA-binding domain in the
hinge region, is the most interesting because it contains a nuclear
export signal [13]. Whether Ser650, Ser424, and Ser514 are poten-
tial targets of GSK-3 to control either nuclear import/export or AR-
stability remains to be elucidated.
In summary, there is experimental evidence that GSK-3 modulates
AR-stability and AR-functions. Although not all GSK inhibitors down-
regulated AR–stability/function, our observations suggest a potential
new therapeutic application for some of these compounds in PCa.
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Table W1. Densitometric Analysis of AR-Protein Levels After Treatment with Pharmacological GSK-3 Inhibitors.
AR-A014418 SB216763 GSK XIII
Control 0.25 μM 0.50 μM Control 3 μM 5 μM Control 4 μM
% Control [AR/Actin] 100 107 ± 11 118 ± 6 100 81 ± 8 70 ± 10 100 88 ± 3
LNCaP prostate cancer cells were grown for 48 hours in RPMI 1640, 10% FBSdcc, antibiotics, and 5-nM R1881 supplemented with different pharmacological GSK-3 inhibitors. Subsequently, cell
extracts were analyzed by Western blot analysis as described in the Materials and Methods section. Expression of AR-protein levels was quantified by densitometry using ChemiCapt/Bio1D software.
Results represent the mean of three different Western blots and are expressed in percent of R1881-treated cells, which were set at 100% (% AR/Actin ± % SD).
Table W2. Densitometric Analysis of AR Protein Levels After Treatment with MG-132 and
SB216763.
Control SB216763 SB216763 + MG-132
% Control [AR/Actin] 100 61 ± 5 95 ± 7
LNCaP cells were incubated with/without 5 μM of the proteasome inhibitor MG-132 for 60 min-
utes, followed by a SB216763 treatment (final concentration 1 μM) for another 60 minutes. Sub-
sequently, R1881 (5 nM) was added to the medium, and the cells were grown for another 6 hours.
Subsequently, cell extracts were analyzed by Western blot analysis: Immunoreactive bands were
quantified by densitometry using ChemiCapt/Bio1D software.
Results represent the mean of four different Western blot experiments. Increase/decrease of AR/
Actin protein level is expressed in % R1881-treated controls, which were set at 100%.
